Initial and serial heart-failure evaluation — ACC/AHA · 2022 guideline reading
2022 AHA/ACC/HFSA heart failure guideline
The guideline groups heart-failure evaluation into clinical assessment, initial laboratory and electrocardiographic testing, biomarkers, genetic evaluation, cardiac imaging, invasive evaluation, monitoring, and functional-capacity assessment. The linked section provides the complete context for each component.
Last source-check date
2026-08-24
Exact source location
Section 4, ‘Initial and Serial Evaluation’, pp. e908–e918
Prepared source-record governance
This record is prepared from a stored source. It is not labelled reviewer-verified because named reviewer provenance has not been documented.
- Clinical reviewer
- Not yet documented.
- Reviewer credentials
- Not yet documented.
- Last source-check date
- 2026-08-24
- Second-review status
- Not yet documented.
- Conflict-of-interest declaration
- Not yet documented.
- Source publication date
- Not yet documented.
- Source access date
- Not yet documented.
- Record version
- Not yet documented.
- Change history
- Not yet documented.
- Next review date
- Not yet documented.
Verification status & editorial record
Status: Prepared source record — reviewer provenance not documented.
Last source-check: 2026-08-24
No formally approved public metadata is currently available for a named reviewer, second-review status, conflict declaration, publication or access date, version history, or next review date for this record.
Verification boundary: This concise reading is limited to a prepared guideline passage, not a recommendation or complete algorithm. Verify the official document, local protocol, and patient context before application.